Emerging Biomarkers for Monitoring Chimeric Antigen Receptor T-Cell Therapy

嵌合抗原受体 医学 细胞疗法 临床试验 疾病 汽车T细胞治疗 免疫疗法 T细胞 疾病监测 肿瘤科 细胞 免疫学 内科学 免疫系统 生物 遗传学
作者
Tewodros Mamo,Alexandra Dreyzin,David F. Stroncek,David H. McKenna
出处
期刊:Clinical Chemistry [Oxford University Press]
卷期号:70 (1): 116-127 被引量:1
标识
DOI:10.1093/clinchem/hvad179
摘要

Abstract BACKGROUND Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of hematologic malignancies and holds promise for solid tumors. While responses to CAR T-cell therapy have surpassed other available options for patients with refractory malignancies, not all patients respond the same way. The reason for this variability is not currently understood. Therefore, there is a strong need to identify characteristics of patients as well as cellular products that lead to an effective response to CAR T-cell therapy. CONTENT In this review, we discuss potential biomarkers that may predict clinical outcomes of CAR T-cell therapy. Based on correlative findings from clinical trials of both commercially available and early-phase products, we classify biomarkers into categories of pre- and post-infusion as well as patient and product-related markers. Among the biomarkers that have been explored, measures of disease burden both pre- and post-infusion, as well as CAR T-cell persistence post-infusion, are repeatedly identified as predictors of disease response. Higher proportions of early memory T cells at infusion appear to be favorable, and tracking T-cell subsets throughout treatment will likely be critical. SUMMARY There are a growing number of promising biomarkers of CAR T-cell efficacy described in the research setting, however, none of these have been validated for clinical use. Some potentially important predictors of response may be difficult to obtain routinely under the current CAR T-cell therapy workflow. A collaborative approach is needed to select biomarkers that can be validated in large cohorts and incorporated into clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
笨笨发布了新的文献求助10
刚刚
1秒前
大卫在分享完成签到,获得积分0
1秒前
3秒前
Dreamer0422发布了新的文献求助10
3秒前
PEX完成签到,获得积分20
6秒前
大模型应助xianyu采纳,获得10
7秒前
慕青应助奋斗的暖阳采纳,获得10
7秒前
积极南蕾发布了新的文献求助10
8秒前
善学以致用应助灰灰喵采纳,获得10
8秒前
王小茹完成签到,获得积分10
8秒前
cheng完成签到 ,获得积分10
8秒前
马里奥完成签到,获得积分10
13秒前
KWang应助跳跃凡桃采纳,获得20
14秒前
震动的千萍完成签到,获得积分10
14秒前
游心怡发布了新的文献求助10
15秒前
专注秋尽完成签到,获得积分10
15秒前
情怀应助Likyliky采纳,获得10
15秒前
FMZ完成签到,获得积分10
17秒前
小可完成签到 ,获得积分10
18秒前
小鬼1004发布了新的文献求助10
19秒前
橙子完成签到 ,获得积分10
20秒前
chen应助乐观的从梦采纳,获得10
20秒前
科目三应助xixi采纳,获得10
22秒前
huangzsdy完成签到,获得积分10
22秒前
23秒前
云中漫步完成签到,获得积分10
23秒前
暴发户发布了新的文献求助30
23秒前
ho完成签到,获得积分10
24秒前
活泼学生完成签到 ,获得积分10
24秒前
感动归尘应助Only采纳,获得10
25秒前
25秒前
努力努力完成签到 ,获得积分10
27秒前
27秒前
jxt2023完成签到,获得积分10
28秒前
内向东蒽发布了新的文献求助300
28秒前
Chairs完成签到,获得积分0
28秒前
你报完成签到,获得积分10
31秒前
枯木完成签到,获得积分10
32秒前
刘汉淼完成签到,获得积分10
32秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
Introduction to Modern Controls, with illustrations in MATLAB and Python 310
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3056768
求助须知:如何正确求助?哪些是违规求助? 2713310
关于积分的说明 7435391
捐赠科研通 2358319
什么是DOI,文献DOI怎么找? 1249367
科研通“疑难数据库(出版商)”最低求助积分说明 607030
版权声明 596259